Abiraterone improves survival in prostate cancer when given before chemo
the ONA take:
Abiraterone significantly extends survival in men with advanced prostate cancer (PCa) if administered before chemotherapy, according to two recent studies.
In one study published in Lancet Oncology, men with aggressive PCa were found to live more than four months longer on average if they received the drug before chemotherapy compared to if they did not.
Led by Johann de Bono, MD, PhD, of The Institute of Cancer Research in London, the authors built upon previous evidence of the drug’s efficacy that was published in 2013 which showed that it increased the time before cancer progression but did not impact overall survival. They compared average survival of 354 men who were given abiraterone before moving on to chemotherapy with 387 men who received placebo instead. Both groups had also received a low dosage of prednisolone, a treatment used along with abiraterone.
Men in the first group lived an average of 34.7 months compared to men in the second group who lived 30.3 months. Additionally, relatively few men experienced severe side effects.
In another study published in Clinical Cancer Research also conducted by UK researchers at The Institute of Cancer Research, the authors cross-referenced data from the same trial on how the men responded to abiraterone or placebo with a detailed genetic analysis of their tumors.
They found that there was a clear link between ERG gene mutation and abiraterone response. Although the drug was found to improve survival regardless of ERG mutations, those with the most pronounced mutations responded particularly well.
Abiraterone significantly extends survival in men with advanced PCa if administered before chemotherapy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|